Advancing Oncolytic Virus Therapies for Hard-to-Treat Cancers
Harnessing oncolytic viruses to destroy tumors and activate the immune system.
With GMP-grade production underway and Phase I/II trials on the horizon, we are advancing a pipeline focused on brain and solid tumors, starting with GBM and expanding to other high-burden cancers.
Our lead candidate has shown strong efficacy in glioblastoma (GBM) models, achieving significant tumor reduction in both cell cultures and animal studies.
Our Science Include
Directly targets and kills cancer cells.Stimulates the immune system for durable anti-cancer responses.
Demonstrated strong efficacy in glioblastoma (GBM) models.Achieved significant tumor reduction in both cell cultures and animal studies.
GMP-grade production currently underway. Phase I/II clinical trials planned in the near future.
Initial focus on GBM. Expansion to other high-burden brain and solid tumors.